Originally published by our sister publication Gastroenterology & Endoscopy News
By Chase Doyle
DENVER—Dose de-escalation of tofacitinib appears to be safe and effective for patients with ulcerative colitis, but physicians should validate response to an initial induction dose before de-escalating therapy, according to data presented at the 2023 Crohn’s and Colitis Congress (abstract P038).
Findings from the retrospective analysis of 162 patients at the University of California, San